Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Section
Access a regularly updated listing of late-stage clinical trials of high relevance to clinicians who provide care to patients who have or are at risk for osteoporosis. Featured in the most recent update are studies on postmenopausal osteoporosis, secondary osteoporosis, osteoporosis in men, hip and vertebral fracture prevention, and therapeutic agents such as bisphosphonates, calcitonin, denosumab, estrogen, odanacatib, parathyroid hormone analogs, estrogen receptor agonists/antagonists, and other drugs in development.
Calcitonin
A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: Oral Calcitonin; Drug: Nasal Calcitonin; Drug: Placebo
Sponsor: Tarsa Therapeutics, Inc.
Active, not recruiting - verified April 2010
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: teriparatide 20 micrograms/day subcutaneous; Drug: salmon calcitonin 100 IU/day subcutaneous
Sponsor: Eli Lilly and Company
Completed - verified October 2007
A Study of the Treatment of Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Post-Menopausal
Interventions: Drug: teriparatide 20 micrograms/day subcutaneous; Drug: salmon calcitonin 100 IU/day subcutaneous
Sponsor: Eli Lilly and Company
Completed - verified October 2007
PTH Comparison in Post Menopausal Women
Condition: Osteoporosis, Post-Menopausal
Interventions: Drug: teriparatide 20 micrograms/day subcutaneous; Drug: calcitonin 100 IU/day subcutaneous
Sponsor: Eli Lilly and Company
Completed - verified October 2007
A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
Condition: Osteoporosis
Intervention: Drug: SMC021 Oral calcitonin
Sponsors: Nordic Bioscience A/S; Novartis
Active, not recruiting - verified July 2010
A Study for Patients With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Salmon Calcitonin
Sponsor: Eli Lilly and Company
Completed - verified October 2009
Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women
Condition: Postmenopause
Intervention: Drug: Salmon calcitonin
Sponsor: University Hospital, Geneva
Active, not recruiting - verified March 2009
